PSYBIO THERAP. (SUB.VT.)

PsyBio Therapeutics Corp has announced the successful completion of its initial pre-Investigational New Drug (IND) application meeting with the US Food and Drug Administration (FDA) as part of the regulatory submission process.  The company said the focus of the pre-IND meeting was to discuss potential indications, manufacturing strategy, and obtain regulatory guidance as it guides its technology forward towards regulatory approval. » Mehr auf companies

PsyBio Therapeutics Corp said it presented 16 abstracts highlighting the biotechnology company's research and development initiatives at two scientific conferences. The abstracts covered topics such as biosynthetic pathway and transcriptional methodologic development; evaluation; screening and optimization of systems and organisms, and increasing bioproduction yields of natural and non-natural products. » Mehr auf companies

PsyBio Therapeutics Corp., a biotechnology company developing a portfolio of psychoactive compounds aimed at the treatment of mental health disorders, told shareholders that it has filed “six additional provisional manufacturing patent applications” to expand its intellectual property portfolio.  The Oxford, Ohio-based biotech said it had filed the applications with the United States Patent and Trademark Office (USPTO) and they cover a “broad range of approaches to PsyBio's biologic methodology. » Mehr auf companies